Because SRX3212P is a potent inhibitor of BRD4BD1 but not BRD4BD2 or PI3K, whereas SRX3212 is a potent inhibitor of both BDs and PI3K, we measured and compared cytotoxic activity of these inhibitors in three cyclinD1 dependent mantle cell lymphoma cell lines (Jeko-1, Mino and Z138), a colon carcinoma cell line (HCT116), a MYCN amplified p53 mutated neuroblastoma cell line (SKNBE2) and a PTEN mutated prostate cancer cell line (PC3) (Fig. 1h). The gene discussed is CCND1; the disease is neuroblastoma.